Yaky Yanay (Insider Trades), CFO, COO and president of Pluristem Therapeutics Inc. (PSTI), a developer of placenta-based cell therapy products, bought 10,000 shares on Nov. 16. The average price per share was $1.52, for a total transaction of $15,200. Pluristem Therapeutics has a market cap of $123.75 million and a P/S ratio of 318.10.
The volume and number of insider buys increased from 2012 to 2015; however, the volume and number of insider sells decreased during this time. There were no insider buys in 2012 or 2013. There were 11 insider buys totaling 94,728 shares in 2014 and six transactions totaling 90,400 shares in 2015. Though month-end price was similar in summer 2012 and September 2014, there were nine insider buys in September 2014, and none during the summer of 2012. 
Yanay bought 62,000 shares of the company in six transactions and sold 69,850 shares in one transaction since January 2011. Pluristem CEO and Chairman Zami Aberman (Insider Trades) also bought 9,900 shares of the company for an average per share price of $1.49 on Nov. 16. For more information about insider trades with Pluristem, click here.
Pluristem Therapeutics reported revenue of $95,000 in the third quarter of 2015, unchanged from the company’s reported revenue in third quarter 2014. Net loss was also similar for the corresponding quarters at $5.911 million, or 9 cents per share, and $5.876 million, or 7 cents per share in 2014 and 2015. Annual net income for Pluristem follows a decreasing trendline. 
The company announced an expansion of its five-year collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapy at Charité – University Medicine Berlin on Oct. 12. Under the five-year agreement, Pluristem and Charite have completed a successful orthopedic Phase I/II study with placental expanded cells in muscle injury.
According to GuruFocus.com information, Pluristem Therapeutics has a business predictability rank of 1 out of 5 stars. For more information about business predictability rank, click here.
Only one guru made a transaction with Pluristem during the third quarter of 2015. Jim Simons (Trades, Portfolio) increased his stake in the company by 24.73%, buying 76,100 shares of Pluristem for an average per share price of $2.17. The total estimated gain of his holding since the second quarter of 2012 is -44%. For more information about guru trades with Pluristem, click here.
For more stock trades of gurus in real time, visit GuruFocus’ Real Time Picks, a Premium Feature. Not a Premium Member of GuruFocus? Try it free for 7 days here.
